Fierce Drug Dev Forum 2019 has ended
Back To Schedule
Tuesday, October 29 • 9:45am - 10:30am
Explore Innovative Deal Constructs and Risk-Sharing Structures for Licensing and Acquisition Deals

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

  • Review the risks and hurdles to watch out for from an accounting point of view
  • Evaluate how robust your governance structure should be before you start to control the development of an options-based asset
  • Discuss the best ways to structure options agreements and how to minimize exposure to your P&L while ensuring the requisite controls needed

avatar for Emily Minkow

Emily Minkow

Chief Business Officer, PREVAIL THERAPEUTICS
Emily Minkow is the Chief Business Officer of Prevail Therapeutics. Prior to Prevail, Emily held positions of increasing responsibility at Celgene Corporation for seven years, most recently as Executive Director of Business Development. There, she led deal evaluation and execution... Read More →
avatar for Marc Schwabish

Marc Schwabish

Senior Vice President, Business Development and U.S. Operations, FUSION PHARMACEUTICALS
Marc Schwabish leads BD and US Operations at Fusion Pharmaceuticals. Fusion is developing radiotherapeutics with its proprietary Fast-ClearTM Linker Technology and was spun-out of a radiopharmaceutical manufacturer in 2017 with a $46M Series A. Dr. Schwabish’s background spans across... Read More →
avatar for Abbas Kazimi

Abbas Kazimi

Vice President, Head of Business Development, NIMBUS THERAPEUTICS
Abbas Kazimi is Vice President of Business Development at Nimbus where he is responsible for corporate and strategic development, establishing partnerships, and leading collaborations. Abbas joined Nimbus in 2014 and has driven key transactions at Nimbus as well as helped lead the... Read More →

Tuesday October 29, 2019 9:45am - 10:30am PDT